CURIS, INC. (CRIS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
32/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCRIS / S&P -5.45% / 15.20% |
LoseCRIS / S&P -62.17% / 15.00% |
LoseCRIS / S&P -76.51% / 50.40% |
| 2026-Q11/3 |
LoseCRIS / S&P -44.44% / -4.33% |
LoseCRIS / S&P -36.95% / 11.30% |
WinCRIS / S&P 125.62% / 27.70% |
| 2025-Q41/3 |
LoseCRIS / S&P -40.36% / 2.65% |
LoseCRIS / S&P -13.43% / 9.00% |
WinCRIS / S&P 99.42% / 13.40% |
| 2025-Q32/3 |
LoseCRIS / S&P -28.45% / 8.12% |
WinCRIS / S&P 13.56% / 4.61% |
WinCRIS / S&P 111.57% / 13.45% |
| 2025-Q22/3 |
LoseCRIS / S&P 10.48% / 10.94% |
WinCRIS / S&P 12.24% / 4.83% |
WinCRIS / S&P 115.23% / 10.63% |
| 2025-Q11/3 |
LoseCRIS / S&P -31.37% / -4.27% |
WinCRIS / S&P 14.17% / 4.98% |
LoseCRIS / S&P -29.60% / 10.57% |
| 2024-Q41/3 |
LoseCRIS / S&P -43.23% / 2.41% |
WinCRIS / S&P 8.83% / 5.25% |
LoseCRIS / S&P -23.36% / 6.15% |
| 2024-Q30/3 |
LoseCRIS / S&P -21.88% / 5.89% |
LoseCRIS / S&P 0.44% / 5.89% |
LoseCRIS / S&P -16.43% / 6.11% |
| 2024-Q20/3 |
LoseCRIS / S&P -36.52% / 4.28% |
LoseCRIS / S&P -0.44% / 5.38% |
LoseCRIS / S&P -17.98% / 5.12% |
| 2024-Q11/3 |
LoseCRIS / S&P -14.75% / 10.56% |
LoseCRIS / S&P -5.67% / 5.71% |
WinCRIS / S&P 12.19% / 5.59% |
| 2023-Q42/3 |
WinCRIS / S&P 93.47% / 11.69% |
LoseCRIS / S&P -1.37% / 6.81% |
WinCRIS / S&P 63.45% / 7.78% |
| 2023-Q31/3 |
LoseCRIS / S&P -60.30% / -3.27% |
LoseCRIS / S&P -1.88% / 7.52% |
WinCRIS / S&P 299.57% / -5.03% |
| 2023-Q21/3 |
WinCRIS / S&P 38.33% / 8.74% |
LoseCRIS / S&P -3.93% / 9.50% |
LoseCRIS / S&P -2734.21% / -8.57% |
| 2023-Q11/3 |
WinCRIS / S&P 9.09% / 7.50% |
LoseCRIS / S&P -1.09% / 10.77% |
LoseCRIS / S&P -1893.02% / -15.69% |
| 2022-Q40/3 |
LoseCRIS / S&P -21.43% / 7.56% |
LoseCRIS / S&P -4.57% / 11.88% |
LoseCRIS / S&P -1200.00% / -17.99% |
| 2022-Q31/3 |
LoseCRIS / S&P -28.57% / -4.88% |
LoseCRIS / S&P -1.21% / 13.47% |
WinCRIS / S&P 429.55% / -1.41% |
| 2022-Q20/3 |
LoseCRIS / S&P -58.82% / -16.10% |
LoseCRIS / S&P 3.74% / 13.71% |
LoseCRIS / S&P -188.37% / 11.04% |
| 2022-Q10/3 |
LoseCRIS / S&P -50.00% / -4.60% |
LoseCRIS / S&P 1.96% / 15.97% |
LoseCRIS / S&P -189.58% / 42.23% |
| 2021-Q40/3 |
LoseCRIS / S&P -39.21% / 11.03% |
LoseCRIS / S&P -1.72% / 15.00% |
LoseCRIS / S&P -176.92% / 96.40% |
| 2021-Q30/3 |
LoseCRIS / S&P -2.97% / 0.58% |
LoseCRIS / S&P -5.05% / 10.77% |
LoseCRIS / S&P CRIS unavailable / 69.42% |
| 2021-Q20/3 |
LoseCRIS / S&P -28.71% / 8.55% |
LoseCRIS / S&P -8.66% / 6.58% |
LoseCRIS / S&P CRIS unavailable / 51.81% |
| 2021-Q11/3 |
WinCRIS / S&P 38.22% / 6.17% |
LoseCRIS / S&P -5.76% / -1.06% |
LoseCRIS / S&P CRIS unavailable / 7.39% |
| 2020-Q42/3 |
WinCRIS / S&P 600.00% / 12.15% |
WinCRIS / S&P 8.31% / -3.72% |
LoseCRIS / S&P CRIS unavailable / -33.42% |
| 2020-Q31/3 |
LoseCRIS / S&P -3.31% / 8.93% |
WinCRIS / S&P 17.17% / -2.04% |
LoseCRIS / S&P CRIS unavailable / -27.10% |
| 2020-Q22/3 |
WinCRIS / S&P 72.86% / 20.54% |
WinCRIS / S&P 18.48% / -0.46% |
LoseCRIS / S&P CRIS unavailable / -27.11% |
| 2020-Q11/3 |
LoseCRIS / S&P -58.82% / -19.60% |
WinCRIS / S&P 12.53% / 3.47% |
LoseCRIS / S&P CRIS unavailable / -14.75% |
| 2019-Q40/3 |
LoseCRIS / S&P -24.11% / 9.07% |
LoseCRIS / S&P -4.07% / 5.36% |
LoseCRIS / S&P CRIS unavailable / 2.99% |
| 2019-Q31/3 |
WinCRIS / S&P 20.43% / 1.70% |
LoseCRIS / S&P -13.38% / 5.02% |
LoseCRIS / S&P CRIS unavailable / 0.21% |
| 2019-Q20/3 |
LoseCRIS / S&P -6.53% / 4.30% |
LoseCRIS / S&P -10.15% / 6.64% |
LoseCRIS / S&P CRIS unavailable / 8.65% |
| 2019-Q11/3 |
WinCRIS / S&P 188.41% / 13.65% |
LoseCRIS / S&P -4.96% / 8.12% |
LoseCRIS / S&P CRIS unavailable / 14.29% |
| 2018-Q40/3 |
LoseCRIS / S&P -61.24% / -13.52% |
LoseCRIS / S&P 5.35% / 9.05% |
LoseCRIS / S&P CRIS unavailable / 18.23% |
| 2018-Q31/3 |
LoseCRIS / S&P 2.89% / 7.71% |
WinCRIS / S&P 21.53% / 10.21% |
LoseCRIS / S&P CRIS unavailable / 19.06% |
| 2018-Q21/3 |
LoseCRIS / S&P -46.77% / 3.43% |
WinCRIS / S&P 26.69% / 9.03% |
LoseCRIS / S&P CRIS unavailable / 14.46% |
| 2018-Q11/3 |
LoseCRIS / S&P -7.14% / -0.76% |
WinCRIS / S&P 29.03% / 7.68% |
LoseCRIS / S&P CRIS unavailable / 12.46% |
| 2017-Q41/3 |
LoseCRIS / S&P -53.02% / 6.64% |
WinCRIS / S&P 31.50% / 7.03% |
LoseCRIS / S&P CRIS unavailable / 13.82% |
| 2017-Q31/3 |
LoseCRIS / S&P -21.16% / 4.48% |
WinCRIS / S&P 23.99% / 5.68% |
LoseCRIS / S&P CRIS unavailable / 17.57% |
| 2017-Q21/3 |
LoseCRIS / S&P -32.01% / 3.09% |
WinCRIS / S&P 10.21% / 4.83% |
LoseCRIS / S&P CRIS unavailable / 17.74% |
| 2017-Q10/3 |
LoseCRIS / S&P -9.74% / 6.07% |
LoseCRIS / S&P -0.18% / 3.67% |
LoseCRIS / S&P CRIS unavailable / 13.32% |
| 2016-Q41/3 |
WinCRIS / S&P 18.01% / 3.82% |
LoseCRIS / S&P -4.46% / 2.09% |
LoseCRIS / S&P CRIS unavailable / 7.05% |
| 2016-Q31/3 |
WinCRIS / S&P 67.31% / 3.85% |
LoseCRIS / S&P -6.70% / 0.20% |
LoseCRIS / S&P CRIS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CRIS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.51% | 20.78% |
| Annualized return | -95.51% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CRIS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.96% | 83.14% |
| Annualized return | -78.81% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CRIS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.96% | 319.30% |
| Annualized return | -53.85% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |